Status:
WITHDRAWN
Neurodevelopmental Effects of Antiseizure Medications (NEAM) - UG3 Phase
Lead Sponsor:
Stanford University
Conditions:
Epilepsy
Eligibility:
All Genders
18-55 years
Phase:
NA
Brief Summary
To compare in-person to remote video assessments in children to determine the reliability of remote evaluations for future neuropsychological assessments and set a precedent for future investigations.
Eligibility Criteria
Inclusion
- Parents able to provide informed consent for themselves and their child
- Access to computer and reliable internet connection for remote testing
- Child of women with epilepsy who was taking antiseizure medications during the pregnancy of the child being enrolled into the current study
- Child between the ages of 24 months and 30 months of age
- Primary language is English
Exclusion
- Child unable to complete the cognitive assessment (e.g., expected IQ\<70)
- Child with a major medical condition (e.g., epilepsy, diabetes, heart disease, active cancer)
- Child who use centrally active medications
Key Trial Info
Start Date :
April 1 2024
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
September 1 2026
Estimated Enrollment :
Patients enrolled
Trial Details
Trial ID
NCT05364853
Start Date
April 1 2024
End Date
September 1 2026
Last Update
August 19 2024
Active Locations (0)
Enter a location and click search to find clinical trials sorted by distance.
No Results Found
We couldn’t find results for the location/zipcode entered or within the selected range. Please check your input or adjust your search.